Patents by Inventor Aijun LU
Aijun LU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12187742Abstract: Provided herein are compounds of the Formula (I), (II), and (III): as well as pharmaceutically acceptable salts thereof, wherein the substituents are those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of oncologic diseases.Type: GrantFiled: October 19, 2020Date of Patent: January 7, 2025Assignee: XRAD Therapeutics, Inc.Inventors: Jianmin Fu, Yaode Wang, Yue Sun, Guosheng Wu, Aijun Lu, Shuang Zhang, Robert Goodnow, Tona Gilmer, Michael Kastan, David Kirsch
-
Publication number: 20240383915Abstract: Provided herein are acyclic oxazepinyl compounds useful in the treatment on cancers.Type: ApplicationFiled: April 6, 2022Publication date: November 21, 2024Applicant: Genentech, Inc.Inventors: Lewis J. GAZZARD, Samantha Alyson GREEN, Elizabeth H. KELLEY, Matthew Leo LANDRY, Sushant MALHOTRA, Benjamin David RAVETZ, Michael SIU, Jack Alexander TERRETT, BinQing WEI, Steven DO, Yun-Xing CHENG, Limin CHENG, Jianfeng XIN, Mingtao HE, Guosheng WU, Yinlei SUN, Cheng SHAO, Aijun LU, Yulai ZHANG
-
Patent number: 11760744Abstract: Provided are fused ring compounds of Formula (I), Formula (II), or Formula (III), as further detailed herein, which are used for the inhibition of Ras proteins, as well as compositions comprising these compounds and methods treatment by their administration.Type: GrantFiled: August 15, 2019Date of Patent: September 19, 2023Assignee: Genentech, Inc.Inventors: Aijun Lu, Sushant Malhotra, Alan G. Olivero, Cheng Shao, Yamin Zhang, Steven Do
-
Publication number: 20230132621Abstract: 1,5-dihydro-2,4-benzodiazepine-3-one derivatives, such as a compound represented by formula I, acts on 5-HT2A and 5-HT2C receptors. The selectivity for 5-HT2A is superior or similar to pimavanserin. The derivative is used for treating schizophrenia or Parkinson’s disease, dementia-related behavioral disorders, and psychosis. The antipsychotic activity of the compound is equivalent to that of pimavanserin, the side effects of sedation and and worsening of exercise are less than those of pimavanserin, and cardiotoxicity is less than that of pimavanserin.Type: ApplicationFiled: October 20, 2022Publication date: May 4, 2023Inventors: Xiangqing XU, Yinli QIU, Qiang GUO, Minquan YU, Song ZHAO, Quxiang LI, Peng JING, Yuanyuan HOU, Yingying DONG, Guosheng WU, Shuang ZHANG, Aijun LU
-
Publication number: 20230002345Abstract: Provided are fused ring compounds of Formula (I), Formula (II), or Formula (III), as further detailed herein, which are used for the inhibition of Ras proteins, as well as compositions comprising these compounds and methods treatment by their administration.Type: ApplicationFiled: August 15, 2019Publication date: January 5, 2023Inventors: Aijun LU, Sushant Malhotra, Alan G. Olivero, Cheng Shao, Yamin Zhang, Steven Do
-
Publication number: 20220315606Abstract: Provided herein are compounds of the Formula (I), (II), and (III): as well as pharmaceutically acceptable salts thereof, wherein the substituents are those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of oncologic diseases.Type: ApplicationFiled: October 19, 2020Publication date: October 6, 2022Inventors: Jianmin FU, Yaode WANG, Yue SUN, Guosheng WU, Aijun LU, Shuang ZHANG, Robert GOODNOW, Tona GILMER, Michael KASTAN, David KIRSCH
-
Publication number: 20220142995Abstract: Provided herein are compounds of formula (I): and pharmaceutically acceptable salts thereof, where the substituents are as described herein. These compounds and their pharmaceutical compositions may be useful in the treatment of oncologic diseases.Type: ApplicationFiled: January 27, 2022Publication date: May 12, 2022Inventors: Jianmin FU, Yaode WANG, Yue SUN, Guosheng WU, Aijun LU, Shuang ZHANG, Robert A. GOODNOW, Tona GILMER, Michael KASTAN, David KIRSCH
-
Patent number: 11034692Abstract: Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.Type: GrantFiled: August 15, 2019Date of Patent: June 15, 2021Assignee: Genentech, Inc.Inventors: Bryan Chan, Blake Daniels, Joy Drobnick, Lewis Gazzard, Timothy Heffron, Malcolm Huestis, Jun Liang, Sushant Malhotra, Rohan Mendonca, Naomi Rajapaksa, Michael Siu, Craig Stivala, John Tellis, Weiru Wang, BinQing Wei, Aihe Zhou, Matthew W. Cartwright, Emanuela Gancia, Graham Jones, Michael Lainchbury, Andrew Madin, Eileen Seward, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu, Baihua Hu, Aijun Lu
-
Patent number: 10913742Abstract: The invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as respiratory disorders or pain.Type: GrantFiled: May 23, 2019Date of Patent: February 9, 2021Assignee: Genentech, Inc.Inventors: Huifen Chen, Daniel Shore, Elisia Villemure, Matthew Volgraf, Baihua Hu, Aijun Lu, Andrew Cridland, Stuart Ward, Francis Beaumier, Martin Dery, Robin Larouche-Gauthier
-
Patent number: 10711004Abstract: The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.Type: GrantFiled: September 3, 2019Date of Patent: July 14, 2020Assignee: Genentech, Inc.Inventors: Huifen Chen, Brian Safina, Daniel Shore, Jack Terrett, Elisia Villemure, Matthew Volgraf, Stuart Ward, Aijun Lu, Robin Larouche-Gauthier, Francis Beaumier, Martin Dery, Lea Constantineau-Forget, Chantal Grand-Maitre, Luce Lepissier
-
Publication number: 20200002340Abstract: The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.Type: ApplicationFiled: September 3, 2019Publication date: January 2, 2020Applicant: Genentech, Inc.Inventors: Huifen CHEN, Brian SAFINA, Daniel SHORE, Jack TERRETT, Elisia VILLEMURE, Matthew VOLGRAF, Stuart WARD, Aijun LU, Robin LAROUCHE-GAUTHIER, Francis BEAUMIER, Martin DERY, Lea CONSTANTINEAU-FORGET, Chantal GRAND-MAITRE, Luce LEPISSIER
-
Patent number: 10435414Abstract: Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.Type: GrantFiled: July 25, 2018Date of Patent: October 8, 2019Assignee: Genentech, Inc.Inventors: Marie-Gabrielle Braun, Keira Garland, Emily Hanan, Hans Purkey, Steven T. Staben, Robert Andrew Heald, Jamie Knight, Calum Macleod, Aijun Lu, Guosheng Wu, Siew Kuen Yeap
-
Publication number: 20190284189Abstract: The invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as respiratory disorders or pain.Type: ApplicationFiled: May 23, 2019Publication date: September 19, 2019Applicant: Genentech, Inc.Inventors: Huifen CHEN, Daniel SHORE, Elisia VILLEMURE, Matthew VOLGRAF, Baihua HU, Aijun LU, Andrew CRIDLAND, Stuart WARD, Francis BEAUMIER, Martin DERY, Robin LAROUCHE-GAUTHIER
-
Patent number: 10407424Abstract: Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.Type: GrantFiled: March 30, 2018Date of Patent: September 10, 2019Assignee: Genentech, Inc.Inventors: Bryan Chan, Naomi Rajapaksa, Michael Siu, Craig Stivala, John Tellis, Weiru Wang, BinQing Wei, Aihe Zhou, Matthew W. Cartwright, Emanuela Gancia, Graham Jones, Blake Daniels, Michael Lainchbury, Andrew Madin, Eileen Seward, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu, Baihua Hu, Aijun Lu, Joy Drobnick, Lewis Gazzard, Timothy Heffron, Malcolm Huestis, Jun Liang, Sushant Malhotra, Rohan Mendonca
-
Publication number: 20190139521Abstract: A tuning ring for adjusting a sound timbre of a drum head includes: a tuning ring body for disposing beneath a bottom surface of the striking portion of the drum head and having an opening so as to reduce the unstable sound timbre and the uncertain fluttering overtone, thereby causing the tuned sound timbre clear and being concentrated to be a thicker sound timbre and optimizing the sound timbre of the drum head. If the present invention is applied to the drum head which has been stretched to a finished state, the tuned sound timbre does not change, thereby achieving the abovementioned optimal quality of the tuned sound timbre.Type: ApplicationFiled: November 6, 2017Publication date: May 9, 2019Inventor: Aijun Lu
-
Patent number: 10280165Abstract: The invention relates to pyridopyrimidinone compounds of formula I or pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4, R5 and R6 are as defined herein, as well as pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.Type: GrantFiled: October 13, 2017Date of Patent: May 7, 2019Assignee: Genentech, Inc.Inventors: Matthew Volgraf, Yu Jiang, Elisia Villemure, Benjamin Sellers, Guosheng Wu, Aijun Lu
-
Patent number: 10179782Abstract: The invention is concerned with the compounds of formula I: and salts thereof and other compounds of formulas II-IX as disclosed herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formulas I-IX as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain or asthma.Type: GrantFiled: February 12, 2016Date of Patent: January 15, 2019Assignee: Genentech, Inc.Inventors: Anthony Estrada, Elisia Villemure, Vishal Verma, Daniel Shore, Matthew Volgraf, Baihua Hu, Aijun Lu
-
Publication number: 20180327420Abstract: Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.Type: ApplicationFiled: July 25, 2018Publication date: November 15, 2018Applicant: Genentech, Inc.Inventors: Marie-Gabrielle Braun, Keira Garland, Emily Hanan, Hans Purkey, Steven T. Staben, Robert Andrew Heald, Jamie Knight, Calum Macleod, Aijun Lu, Guosheng Wu, Siew Kuen Yeap
-
Publication number: 20180282328Abstract: Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.Type: ApplicationFiled: March 30, 2018Publication date: October 4, 2018Applicant: Genentech, Inc.Inventors: Bryan Chan, Blake Daniels, Joy Drobnick, Lewis Gazzard, Timothy Heffron, Malcolm Huestis, Jun Liang, Sushant Malhotra, Rohan Mendonca, Naomi Rajapaksa, Michael Siu, Craig Stivala, John Tellis, Weiru Wang, BinQing Wei, Aihe Zhou, Matthew W. Cartwright, Emanuela Gancia, Graham Jones, Michael Lainchbury, Andrew Madin, Eileen Seward, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu, Baihua Hu, Aijun Lu
-
Patent number: 10065970Abstract: Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.Type: GrantFiled: September 7, 2016Date of Patent: September 4, 2018Assignee: Genentech, Inc.Inventors: Marie-Gabrielle Braun, Keira Garland, Emily Hanan, Hans Purkey, Steven T. Staben, Robert Andrew Heald, Jamie Knight, Calum Macleod, Aijun Lu, Guosheng Wu, Siew Kuen Yeap